Bracco Expands Contrast Management Tech in Europe with ACIST Pro Launch
Event summary
- Bracco Group launched the ACIST Pro™ Diagnostic System in select European markets on February 12, 2026.
- The ACIST Pro™ system builds on the existing ACIST CVi® technology, automating contrast delivery in image-guided cardiovascular procedures.
- Clinical data suggests the ACIST CVi® system reduces contrast use by 45ml, CI-AKI risk by 30%, and saves an average of 5 minutes per case.
- The system was previously launched in Japan in 2025, and FDA 510(k) clearance is pending in the United States.
- Bracco Imaging’s CEO, Fulvio Renoldi Bracco, highlighted the system's role in advancing precision imaging across specialties.
The big picture
The launch of ACIST Pro™ underscores the ongoing trend towards automation and precision in interventional cardiology, driven by a desire to improve patient outcomes and reduce healthcare costs. Bracco’s acquisition of ACIST positions them to capitalize on this trend, leveraging ACIST’s technology to complement Bracco’s broader diagnostic imaging portfolio. The system's success will be a key indicator of Bracco's ability to integrate acquired businesses and drive innovation within its medical device segment, which represents a significant portion of the company's €2 billion annual revenue.
What we're watching
- Regulatory Headwinds
- The success of ACIST Pro™ in Europe will depend on ongoing adherence to the MDR and potential future revisions to EU medical device regulations, which could impact market access and approval timelines.
- US Adoption
- The timing and outcome of the FDA 510(k) clearance process will be critical for broader market penetration, as the US represents a significant revenue opportunity for Bracco and ACIST.
- Competitive Landscape
- How effectively Bracco can differentiate ACIST Pro™ from competing contrast management systems, particularly as other players innovate in this space, will determine its long-term market share and profitability.
Related topics